FERMENTA vs SHUKRAPHAR: Stock Comparison
SHUKRA PHARMACEUTICALS L is the larger company by market capitalisation. FERMENTA BIOTECH shows a lower P/E, a higher dividend yield and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
FERMENTA leads 5; SHUKRAPHAR leads 2 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | FERMENTA | SHUKRAPHAR |
|---|---|---|
| Live Price | ₹446.4 | ₹79.88 |
| Day Change | 7.2% | -0.03% |
| Volume | 3.57 L | 51.81 L |
| 52-Week High | ₹582.65 | ₹84.2 |
| 52-Week Low | ₹248.85 | ₹40.06 |
| Distance from 52W High | -23.38% | -5.13% |
Valuation
| Metric | FERMENTA | SHUKRAPHAR |
|---|---|---|
| Market Cap | ₹1,319 Cr | ₹3,494 Cr |
| P/E Ratio | 25.96x | 79.48x |
| P/B Ratio | 3.15x | 29.55x |
| EPS | ₹3.31 | ₹0.3 |
| Book Value | ₹136.1 | ₹2.05 |
| Dividend Yield | 0.84% | 0.01% |
Growth
| Metric | FERMENTA | SHUKRAPHAR |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0% | 271.95% |
| Qtr Profit Growth | 0% | 742.72% |
Profitability & Leverage
| Metric | FERMENTA | SHUKRAPHAR |
|---|---|---|
| ROE | 17.54% | — |
| ROCE | 16.48% | — |
| Net Margin | 13.37% | 0% |
| Operating Margin | 20.44% | — |
| Debt to Equity | 0.27x | — |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | FERMENTA | SHUKRAPHAR |
|---|---|---|
| Promoter Holding | 56.47% | 51.15%▲ 0.19 pp |
| FII Holding | 1.05%▲ 0.92 pp | 0.44%▲ 0.44 pp |
| DII Holding | 0%▼ 0.04 pp | 0.22%▲ 0.11 pp |
| Public Holding | 36.43%▲ 3.23 pp | 48.2%▼ 0.72 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: FERMENTA BIOTECH and SHUKRA PHARMACEUTICALS L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.